Insider information

Want to stay updated? Subscribe to our newsletters. For free.

Have questions? Our live support would be happy to help you.

You are here: epigenomics > News & Investors > Insider information

Insider information

15. July 2019 - 15:49 (CEST)

Chinese Patent Reexamination Department partially invalidates Epigenomics’ patent claims for Septin9

Read more

03. May 2019 - 0:40 (CEST)

CMS accepts Epigenomics’ application for NCD review

Read more

06. March 2019 - 20:57 (CEST)

Epigenomics AG terminates collaboration with Chinese licensing partner and announces anticipated revenue growth in 2019 outlook

Read more

Press releases

24. July 2019

Study Published in American Health Drug Benefits Suggests that Non-Invasive Screening Methods, Including Epi proColon®, Could Be A Cost-Effective Option To Help Achieve Target U.S. Colorectal Cancer Screening Rates

Read more

11. July 2019

Epigenomics AG Receives MedTech Outlook‘s 2019 Top 10 In-Vitro Diagnostics Award

Read more

17. June 2019

New Clinical Data Support the Utility of Epi proColon® Blood Test for Colorectal Cancer (CRC) Screening in Patients with Lynch Syndrome (LS), the Most Common Hereditary CRC Syndrome

Read more